Search results
Results from the WOW.Com Content Network
Nirmatrelvir/ritonavir is under investigation, so its side effects have yet to be fully evaluated and may not be completely known. [ 19 ] Other side effects of nirmatrelvir/ritonavir may include hypersensitivity reactions , liver toxicity , and development of HIV drug resistance in people with uncontrolled or undiagnosed HIV infection .
The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. [11] [13] These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects and toxicity. [8]
Common side effects include headache, tiredness, trouble sleeping, abdominal pain, weight loss, and rash. [5] Serious side effects may include high blood lactate levels and enlargement of the liver. [7] Use of this medication during pregnancy does not appear to harm the fetus, but this has not been well studied. [1]
Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is almost always used in combination with other antiretroviral drugs. Nelfinavir is an orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (K i = 2 nM) and is widely prescribed in combination with HIV reverse transcriptase ...
Ribbon diagram of the protein with the drug shown as sticks. The catalytic residues (His41, Cys145) are shown as yellow sticks. Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor.
The drug was also shown to reduce the viral load at day 4 in treated patients compared to the placebo group. Side effects were mostly mild and infrequent, with the most common being nausea (1.5% vs. 0.2%) and skin rash (3.3% vs. 0.3%), which occurred more often in the olgotrelvir group.
Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3. [5]: 248 Paritaprevir was a component of Viekira Pak and Technivie. [6] In May 2018, the FDA announced that Technivie and Viekira were to be discontinued.
Tenofovir disoproxil is a pro-drug form of tenofovir phosphonate, which is liberated intracellularly and converted to tenofovir disphophate. [32] It is marketed by Gilead Sciences (as the fumarate, abbreviated TDF). [33] Tenofovir disoproxil is also available in pills which combine a number of antiviral drugs into a single dose.